Information for patients and families on Clearview's policies regarding COVID-19

(888) 374-1015
Click to call us toll free: (888) 374-1015

Disease States

Table of Contents

Breast Cancer

NCT03562637: Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) following Neoadjuvant or Adjuvant Chemotherpay

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT03562637?term=OBI&cond=TNBC+-+Triple-Negative+Breast+Cancer&draw=2&rank=1

CCI Research Team Contact:

Avitra Bone, RN NSN ONC
256-705-4283
avitrab@ccihsv.com

Colorectal Cancer

Gastric Cancer

Genitourinary Cancer

NCT02599324 A Study to Evaluate Ibrutinib Combination Therapy in Patients with Selected Gastrointestinal and Genitourinary Tumors

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02599324?term=Pharmacyclics&cond=Urothelial+Carcinoma&draw=2&rank=1

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

Leukemia

NCT03801525: Study to Assess the Efficacy and Safety of Ublituximab Plus Umbralisib in Combination with Venetoclax in Subjects with CLL (ULTRA-V)

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT03801525?term=TG+Therapeutics&recrs=a&cond=CLL&draw=1&rank=2

CCI Research Team Contact:

Avitra Bone, RN BSN OCN
256-705-4283
avitrab@ccihsv.com

NCT04116437: Study of Zanubrutinib (BGB-3111) in Participants with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT04116437?term=Beigene&cond=CLL&draw=2&rank=3

CCI Research Team Contact:

Leslie Smoot, RN
256-705-4246
leslies@ccihsv.com

Lung Cancer

NCT03840915 Study M7824 in Combination with Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT03840915?term=EMD&cond=NSCLC+Stage+IV&cntry=US&draw=2&rank=3

CCI Research Team Contact:

Leslie Smoot, RN
256-705-4246
leslies@ccihsv.com

NCT03906071 Phase 3 Study of Siltravatinib Plus Nivolumab vs Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT03906071?term=Mirati&cond=NSCLC&draw=2&rank=1

CCI Research Team Contact:

Leslie Smoot, RN
256-705-4246
leslies@ccihsv.com

Lymphoma

NCT02793583: Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 Alone in Patients with Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT02793583?term=TG+Therapeutics&cond=Follicular+Lymphoma&draw=2&rank=4

CCI Research Team Contact:

Avitra Bone, RN, BSN, OCN
256-705-4283
avitrab@ccihsv.com

NCT04116437: Study of Zanubrutinib (BGB-3111) in Participants with Previously Treated Chronic Lymphocytic Lukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT04116437?term=Beigene&cond=CLL&draw=2&rank=3

CCI Research Team Contact:

Leslie Smoot, RN
256-705-4246
leslies@ccihsv.com

NCT03778073: Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma

Trial Information:
https://clinicaltrials.gov/ct2/show/NCT03778073?term=TG+Therapeutics&cond=B-cell+Lymphoma&draw=2&rank=3

CCI Research Team Contact:

Leslie Smoot, RN
256-705-4246
leslies@ccihsv.com

Pancreatic Cancer

No current trials

Supportive Care and Disease Registries

NCT03836105 CemiplimAB Survivorship Epidemiology (CASE)
Trial Information:
https://clinicaltrials.gov/ct2/show/NCT03836105?term=Regeneron&recrs=a&cond=Squamous+Cell+Carcinoma&cntry=US&state=US%3AAL&draw=2&rank=1

CCI Research Team Contact:

Lisa Chapuran
256-327-5740
lchapuram@ccihsv.com

NCT04180176 A Prospective Clinicogenomic Program (GX41563)
Trial Information:
https://clinicaltrials.gov/ct2/show/NCT04180176?term=NCT04180176&draw=2&rank=1

CCI Research Team Contact:

Megan Moseley
256-327-4227
meganh@ccihsv.com

DLS ABRT Trial (BioBank)
Trial Information:
https://www.dls.com/biopharma/

CCI Research Team Contact:

Megan Moseley
256-327-4227
meganh@ccihsv.com